

STATE OF COLORADO

Bill Ritter, Jr., Governor
Ned Calonge, M.D., Interim Executive Director

Dedicated to protecting and improving the health and environment of the people of Colorado

4300 Cherry Creek Dr. S. Laboratory Services Division
Denver, Colorado 80246-1530 8100 Lowry Blvd.
Phone (303) 692-2000 Denver, Colorado 80230-6928
TDD Line (303) 691-7700 (303) 692-3090
Located in Glendale, Colorado
<http://www.cdphe.state.co.us>



Colorado Department
of Public Health
and Environment

NOTICE OF PUBLIC RULE-MAKING HEARING BEFORE THE COLORADO BOARD OF HEALTH

NOTICE is hereby given pursuant to the provisions of Section 24-4-103, C.R.S., that the Colorado Board of Health will conduct a public rule-making hearing on **January 20, 2010** in the Sabin-Cleere Conference Room of the Colorado Department of Public Health and Environment, Bldg. A, First Floor, 4300 Cherry Creek Drive, South, Denver, CO 80246, to consider the promulgation of **amendments to 6 CCR 1009-1, Rules and Regulations Pertaining to Epidemic and Communicable Disease Control**. The Board meeting commences in the morning. For the specific time this hearing is scheduled, please consult the meeting agenda on the Board's Web site at <http://www.cdphe.state.co.us/op/bh/index.html> on or after Friday, January 8, 2010, or call (303) 692-3464.

The purpose of this hearing is to receive public comments on proposed amendments to 6 CCR 1009-1, Rules and Regulations Pertaining to Epidemic and Communicable Disease Control, Regulations 1, 3 and 11. The proposed changes include adding chlamydia (currently on the list of laboratory reportable conditions) to the list of diseases that require provider reporting within seven days (Regulation 1, List B) and clarifying hepatitis C laboratory reporting requirements (Regulation 3). The expansion of chlamydia surveillance will allow the Department to more adequately characterize and monitor the growing problem of these infections, and better target screening, prevention and education efforts. Clarifying the language for hepatitis C reporting will enhance surveillance and provide needed information in the initial report. In addition, the proposed amendments also include adding hepatitis C to the list of sexually transmitted infections (Regulation 11), as well as several technical changes to update the terminology in Regulation 11.

The proposed rules have been developed by the Disease Control and Environment Epidemiology Division of the Colorado Department of Public Health and Environment pursuant to Section 25-1-122, Section 25-4-401, and Section 25-4-402 C.R.S.

Copies of the proposed rules may be obtained by contacting the Colorado Department of Public Health and Environment, Disease Control and Environmental Epidemiology Division DCEED-STD/HIV-A3, 4300 Cherry Creek Drive S., Denver, CO 80246, (303) 692-2756. The proposed amendments will also be available on the Board's Web site at <http://www.cdphe.state.co.us/op/bh/index.html> under "Notices of Upcoming Public Rulemaking Hearings and Draft Proposed Rules."

The Board encourages all interested persons to participate in the hearing by providing written data, views, or comments, or by making oral comments at the hearing. At the discretion of the Chair, oral testimony at the hearing may be limited to five minutes or less depending on the number of persons wishing to comment.

The Board requests submission of written materials at least seven days prior to the hearing date, to allow the Board sufficient time to review the comments prior to the meeting. Persons wishing to submit written comments or views should submit them to:

Colorado Board of Health
ATTN: Linda Shearman, Program Assistant
Colorado Department of Public Health and Environment
4300 Cherry Creek Drive South EDO-A5
Denver, Colorado 80246-1530
FAX: 303-691-7702, e-mail: linda.shearman@state.co.us

The proposed revisions to be considered at the hearing, together with the proposed statement of basis and purpose, specific statutory authority and regulatory analysis will be available for inspection at the above address by any person at least five working days prior to the hearing.

Dated this 30th day of November 2009.


Ned Calonge, MD
Interim Executive Director

